Contineum Therapeutics, Inc. Class A Common Stock
CTNMNASDAQHealthcare● Active
$11.53
+$0.04(+0.35%)
Market Cap$431064892
P/E Ratio—
52W High$16.33
52W Low$3.57
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTNM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.39
Est. -$0.55 · +29.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
CTNM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.46 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.55 | -$0.39 | +29.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.50 | -$0.49 | +2.0% | — | $0.01B | — |
| ▲ Q4 FY2025 | Oct 30, 2025 | -$0.58 | -$0.45 | +22.4% | — | $0.01B | — |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.56 | -$0.62 | -10.7% | — | $0.01B | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.56 | -$0.62 | -10.7% | — | $0.01B | — |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.44 | -$0.56 | -27.3% | — | — | — |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$0.41 | -$0.40 | +2.4% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.39
EPS Est.
-$0.55
EPS Surpr.
+29.1%
Revenue
—
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.49
EPS Est.
-$0.50
EPS Surpr.
+2.0%
Revenue
—
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.58
EPS Surpr.
+22.4%
Revenue
—
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.62
EPS Est.
-$0.56
EPS Surpr.
-10.7%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.62
EPS Est.
-$0.56
EPS Surpr.
-10.7%
Revenue
—
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$0.56
EPS Est.
-$0.44
EPS Surpr.
-27.3%
Revenue
—
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$0.40
EPS Est.
-$0.41
EPS Surpr.
+2.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.33 | $-0.33 | $-0.33 | 2 |
| Q3 FY2028 | $-0.33 | $-0.33 | $-0.33 | 2 |
| Q2 FY2028 | $-0.32 | $-0.32 | $-0.32 | 2 |
| Q1 FY2028 | $-0.32 | $-0.32 | $-0.32 | 2 |
| Q4 FY2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2027 | $-0.48 | $-0.48 | $-0.48 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +29.1% | $14.15 | $14.39 | +1.70% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +2.0% | $14.86 | $13.81 | -7.07% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +22.4% | $10.90 | $10.54 | -3.30% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -10.7% | $5.80 | $6.00 | +3.45% |
| ▼ Q2 FY2025 | May 14, 2025 | -10.7% | $3.81 | $3.84 | +0.79% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -27.3% | $6.10 | $6.44 | +5.57% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +2.4% | $16.60 | $17.24 | +3.86% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -11.4% | $17.32 | $16.27 | -6.06% |
Q2 FY2026+1.70%
Report Date
May 5, 2026
EPS Beat/Miss
+29.1%
Price Before
$14.15
Price After
$14.39
Q1 FY2026-7.07%
Report Date
Mar 5, 2026
EPS Beat/Miss
+2.0%
Price Before
$14.86
Price After
$13.81
Q4 FY2025-3.30%
Report Date
Oct 30, 2025
EPS Beat/Miss
+22.4%
Price Before
$10.90
Price After
$10.54
Q3 FY2025+3.45%
Report Date
Aug 5, 2025
EPS Beat/Miss
-10.7%
Price Before
$5.80
Price After
$6.00
Q2 FY2025+0.79%
Report Date
May 14, 2025
EPS Beat/Miss
-10.7%
Price Before
$3.81
Price After
$3.84
Q1 FY2025+5.57%
Report Date
Mar 6, 2025
EPS Beat/Miss
-27.3%
Price Before
$6.10
Price After
$6.44
Q4 FY2024+3.86%
Report Date
Nov 6, 2024
EPS Beat/Miss
+2.4%
Price Before
$16.60
Price After
$17.24
Q3 FY2024-6.06%
Report Date
Aug 13, 2024
EPS Beat/Miss
-11.4%
Price Before
$17.32
Price After
$16.27
Avg Beat Reaction-1.20%
Avg Miss Reaction+0.94%
Beat Rate4 / 8 quarters
Largest Move-7.07% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTNM ends December
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.39 — beating the analyst consensus of $-0.55 by +29.1%. CTNM has beaten EPS estimates for 3 consecutive quarters. The next CTNM earnings date is expected around September 1, 2026.
Each quarter, investors track CTNM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTNM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTNM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTNM earnings · 5 questionsContineum Therapeutics, Inc. Class A Common Stock's next earnings report is expected around September 1, 2026. CTNM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTNM historically reports after market close (AMC).
CTNM earnings datewhen is CTNM earningsCTNM next earnings datewhen does CTNM report earningsCTNM earnings calendar
▸ Source: FMP · Contineum Therapeutics, Inc. Class A Common Stock SEC filings · US GAAP · Contineum Therapeutics, Inc. Class A Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026